Clinical Trial Detail

NCT ID NCT03246958
Title Nivolumab Plus Ipilimumab in Thyroid Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

thyroid gland cancer

Therapies

Ipilimumab + Nivolumab

Age Groups: senior adult

No variant requirements are available.